RE:RE:EPIX from US$1.6 to US$32 on P1 cancer data,18 months Those were patients from the initial cohort at 200mg!
The dose escalation plan is to have 5 cohorts at 200, 400, 600, 800 and 1000mg. Kind of an ideal scenario really... A sign of efficacy just 6 months into dosing!
qwerty22 wrote: So one out of three patients. Is that the first 3 patients in the dose escalation phase or first 3 at therapeutic levels or first three after MTD reached?Just curious.
Spartrap wrote:
Here we go,that small canadian company ESSA Pharma I was talking about the other day just published first human data today. Briefly touched US$32 on the news (US$1B MC).
"One out of three patients who completed 12 weeks of therapy experienced a prostate-specific antigen decline (PSA) of more than 50% after three cycles of EPI-7386 therapy (12 weeks) with ongoing continued PSA declines continuing through six cycles of therapy, despite previously having failed enzalutamide and abiraterone acetate"
One patient response. 20 bagger. In 18 months. After huge dilution.
I was buying it as low as US$1.6 in august 2019 after a reverse merger followed by a raise. The RM diluted by roughly 100% in May 2019 and was quickly followed in August by a raise that was again another massive 130% dilutive.
SP went up regularly during all that time, with IND in March 2020 followed by P1 dosing in July 2020.
Then went into the US$20's on news than Jenssen wanted to collaborate for a combination trial back in January 13th. There you see it : Jenssen *new* about the response months before the data came out. That's the beauty of early open label trials. Leaks to BP.